Linifanib (ABT-869)
Linifanib (ABT-869, AL39324, RG3635) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Linifanib (ABT-869) induces autophagy and apoptosis. Phase 3.
| Trivial name | AL39324,RG3635 |
| Catalog Number | S1003 |
| Molecular Formula | C21H18FN5O |
| CAS# | 796967-16-3 |
| Inchi | InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28) |
| Inchi Key | MPVGZUGXCQEXTM-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/ABT-869.html |
| Additional Information | https://file.selleck.cn/downloads/struct/Linifanib-ABT-869-chemical-structure-S1003.gif |